#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects

June 7, 2026 02:30 PM EDT R&DPharmaGLP-1 drugs Near­ly 1 in 5 pa­tients quit Boehringer and Zealand’s obe­si­ty shot over side ef­fects Elizabeth Cairns Senior biopharma journalist Boehringer In­gel­heim’s obe­si­ty as­set sur­vo­du­tide, which it li­censed from Zealand Phar­ma, has shown high rates of dis­con­tin­u­a­tions in its Phase 3 obe­si­ty study. In April … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER